{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:06:31Z","timestamp":1768093591870,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Pharmaceutical K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11523-022-00929-3","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T17:18:01Z","timestamp":1669655881000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study"],"prefix":"10.1007","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct01715285","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-5869","authenticated-orcid":false,"given":"Yosuke","family":"Koroki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-0056","authenticated-orcid":false,"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"929_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"key":"929_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"key":"929_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.euros.2021.11.012","volume":"36","author":"Y Koroki","year":"2022","unstructured":"Koroki Y, Taguri M, Matsubara N, Fizazi K. Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study. Eur Urol Open Sci. 2022;36:51\u20138. https:\/\/doi.org\/10.1016\/j.euros.2021.11.012.","journal-title":"Eur Urol Open Sci."},{"key":"929_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. STAMPEDE Trials Collaborative Group. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151:422\u201334. https:\/\/doi.org\/10.1002\/ijc.34018.","journal-title":"Int J Cancer"},{"key":"929_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. PEACE-1 Investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1.","journal-title":"Lancet"},{"key":"929_CR6","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30688-6.","journal-title":"Lancet Oncol"},{"key":"929_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","volume":"71","author":"JS de Bono","year":"2017","unstructured":"de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;71:656\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.033.","journal-title":"Eur Urol"},{"key":"929_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hern\u00e1n","year":"2000","unstructured":"Hern\u00e1n MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561\u201370. https:\/\/doi.org\/10.1097\/00001648-200009000-00012.","journal-title":"Epidemiology"},{"key":"929_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/aje\/kwp418","volume":"171","author":"D Westreich","year":"2010","unstructured":"Westreich D, Cole SR, Tien PC, Chmiel JS, Kingsley L, Funk MJ, et al. Time scale and adjusted survival curves for marginal structural Cox models. Am J Epidemiol. 2010;171:691\u2013700. https:\/\/doi.org\/10.1093\/aje\/kwp418.","journal-title":"Am J Epidemiol"},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0169-2607(97)00043-6","volume":"54","author":"H Heinzl","year":"1997","unstructured":"Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed. 1997;54:201\u20138. https:\/\/doi.org\/10.1016\/s0169-2607(97)00043-6.","journal-title":"Comput Methods Programs Biomed"},{"key":"929_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/biom.13296","volume":"77","author":"Y Hagiwara","year":"2021","unstructured":"Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2021;77:702\u201314. https:\/\/doi.org\/10.1111\/biom.13296.","journal-title":"Biometrics"},{"key":"929_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"key":"929_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"key":"929_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046.","journal-title":"Eur Urol"},{"key":"929_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"key":"929_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","volume":"21","author":"EJ Chen","year":"2015","unstructured":"Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, et al. Abiraterone treatment in castration\u2013resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21:1273\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1220.","journal-title":"Clin Cancer Res"},{"key":"929_CR17","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","volume":"15","author":"S Prekovic","year":"2016","unstructured":"Prekovic S, van Royen ME, Voet AR, Geverts B, Houtman R, Melchers D, et al. The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther. 2016;15:1702\u201312. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0892.","journal-title":"Mol Cancer Ther"},{"key":"929_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28:1508\u201316. https:\/\/doi.org\/10.1093\/annonc\/mdx155.","journal-title":"Ann Oncol"},{"key":"929_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2018.09.049","volume":"75","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, et al. Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:368\u201373. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.049.","journal-title":"Eur Urol"},{"key":"929_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2188\/jea.JE20210145","volume":"31","author":"K Shiba","year":"2021","unstructured":"Shiba K, Kawahara T. Using propensity scores for causal inference: pitfalls and tips. J Epidemiol. 2021;31:457\u201363. https:\/\/doi.org\/10.2188\/jea.JE20210145.","journal-title":"J Epidemiol"},{"key":"929_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550\u201360. https:\/\/doi.org\/10.1097\/00001648-200009000-00011.","journal-title":"Epidemiology"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T06:33:10Z","timestamp":1676615590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00929-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"28 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The LATITUDE study was funded by Janssen Research & Development. Editorial support of this study was funded by Janssen Pharmaceutical K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YK is an employee of Janssen Pharmaceutical K.K. and holds stock in Johnson & Johnson. MT has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the local institutional review boards for each site and conformed with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent, including permission for patient data to be used in post hoc analyses such as the present study, was obtained from all individual participants included in the LATITUDE study (ClinicalTrials.gov, NCT01715285).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The code used during the current study is available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The data sharing policy of the study sponsor, Janssen Pharmaceutical Companies of Johnson & Johnson, is available online. Requests for access to the study data can be submitted through the Yale Open Data Access Project site. For Janssen\u2019s data sharing policy, see . For the Yale Open Data Access Project, see .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"YK and MT contributed to the study\u2019s conception and design. Material preparation and analysis were performed by YK. The first draft of the manuscript was written by YK, and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}